We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Takara Bio enters into a license agreement of RetroNectin® with Fondazione Telethon ETS

A lab worker pipetting into an agar dish.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Takara Bio Inc. announces that it has entered into a License Agreement with non-profit/charity organization, Fondazione Telethon ETS (“Telethon”) (https://www.telethon.it/en), Italy, under which Takara Bio grants Telethon a commercial license to use RetroNectin®. Under this agreement, Takara Bio provides Telethon with reliable supplies of RetroNectin®.

The technologies licensed to Telethon are based on Takara Bio’s proprietary RetroNectin® method, which includes a technology enabling highly efficient gene transduction to cells by retrovirus/lentivirus vector and expansion of T-cells with high efficiency. With such advantages, RetroNectin® method is one of the mostly used standard protocols utilized for “Engineered Gene Therapy”, which includes promising TCR and CAR gene therapies recently raising higher expectations, as well as “Hematopoietic stem cell Gene Therapy”.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE
Under the agreement signed with Takara Bio, Telethon is allowed to use RetroNectin® for production of its cell & gene therapy products, one of which is Strimvelis, a rare disease treatment targeting Adenosine deaminase deficiency.

Takara Bio is promoting supply of RetroNectin® to clinical development of Engineered gene and cell Therapy actively pursued worldwide in recent years, and expects higher sales growth in the future.